Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from ZyVersa Therapeutics ( (ZVSA) ).
On July 8, 2025, ZyVersa Therapeutics entered into a warrant exercise inducement agreement with a holder of its Series A-2 and Series A-3 Common Stock purchase warrants, reducing the exercise price to $0.67 per share. This agreement, facilitated by A.G.P./Alliance Global Partners, aims to generate approximately $2.05 million in gross proceeds, intended for working capital and corporate purposes, pending stockholder approval for the issuance of new warrants.
The most recent analyst rating on (ZVSA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on ZyVersa Therapeutics stock, see the ZVSA Stock Forecast page.
Spark’s Take on ZVSA Stock
According to Spark, TipRanks’ AI Analyst, ZVSA is a Underperform.
ZyVersa Therapeutics faces significant financial challenges with no revenue and ongoing losses. Technical indicators show bearish momentum, and the negative P/E ratio suggests overvaluation concerns. The lack of dividend yield further limits investment appeal.
To see Spark’s full report on ZVSA stock, click here.
More about ZyVersa Therapeutics
ZyVersa Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on the development of innovative drugs and therapies. The company is involved in creating treatments for various medical conditions, with a market focus on advancing therapeutic solutions.
Average Trading Volume: 5,686,698
Technical Sentiment Signal: Sell
Current Market Cap: $3.22M
For a thorough assessment of ZVSA stock, go to TipRanks’ Stock Analysis page.